ReneSola Ltd (SOL) Stock

SOL has signed a PPA for a 15 MWp solar farm in Poland, expanding its footprint in Europe's growing solar market.

SOL announces that it has closed the second phase of its BESS portfolio under the DSA with Arpinge.

NORWALK, Conn. , Dec. 23, 2024 /PRNewswire/ -- Emeren Group Ltd ("Emeren" or the "Company") (www.emeren.com) (NYSE: SOL), a leading global solar project developer, owner, and operator, today announced the closing of the second round of its Battery Energy Storage System (BESS) portfolio under the Development Service Agreement (DSA) with Arpinge, a permanent capital vehicle focused on sustainable infrastructure in Italy.

Toronto, Ontario--(Newsfile Corp. - December 11, 2024) - SOL Global Investments Corp. (CSE: SOL) (OTC Pink: SOLCF) (FSE: 9SB) ("SOL" or "the Company") is pleased to announce that it has successfully repaid $3.4 million of its outstanding debt to its senior lender, Braebeacon Holdings Inc., decreasing the loan balance to $10.2 million. This repayment aligns with SOL Global's broader financial objectives and reflects the Company's ongoing commitment to strengthening its financial position and reducing leverage.

100% of Net Proceeds Will be Used for the Purchase of Additional Solana Tokens Toronto, Ontario--(Newsfile Corp. - December 3, 2024) - SOL Global Investments Corp. (CSE: SOL) (OTC Pink: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") is pleased to announce that it has closed its previously announced brokered private placement. The Company sold 18,000,000 units of the Company (each, a "Unit") at a price of $0.20 per Unit for aggregate gross proceeds to the Company of $3,600,000 (the "Offering").

SOL-1 is the first registrational trial for AXPAXLI™ in wet AMD Topline clinical data from SOL-1 expected in Q4 2025 Active clinical trial sites enrolling patients directly into second registrational trial, SOL-R, while additional sites continue to be activated BEDFORD, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that more than 300 patients have been randomized in the SOL-1 Phase 3 trial for AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), and the trial is expected to close randomization this week.

NORWALK, Conn. , Nov. 21, 2024 /PRNewswire/ -- Emeren Group Ltd ("Emeren" or the "Company") (www.emeren.com) (NYSE: SOL), a leading global solar project developer, owner, and operator, today announced its participation in the following investor conferences: Janney's 2nd Annual Clean Energy Investment Symposium on December 4-5, 2024, in New Orleans, LA.

Emeren Group Ltd (NYSE:SOL ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Gary Dvorchak - Managing Director, The Blueshirt Group Yumin Liu - CEO Ke Chen - CFO Conference Call Participants Philip Shen - Roth Capital Partners Operator Hello, ladies and gentlemen. Welcome and thank you for standing by, for Emeren Group Limited Third Quarter 2024 Earnings Conference Call.

Emeren Group's new business model focuses on solar project development in Europe, with a significant project pipeline and expected profitability improvements in H2 FY24. Despite positive guidance, Emeren reported a revenue decline and net loss in H1 FY24, raising doubts about achieving FY24 targets. The company has a high cash burn rate, with net cash dropping significantly, and may face increased debt or shareholder dilution without improved operating results.